Serotonin transporter polymorphism, depressive symptoms, and emotional impulsivity among advanced breast cancer patients
- 306 Downloads
This study tested a theory linking a marker of low serotonergic function to both depression and impulsivity in a sample of advanced breast cancer patients, among whom elevated depressive symptoms and difficulty regulating emotions are commonly reported.
A total of 95 patients provided blood samples for serotonin transporter polymorphic region of the gene (5-HTTLPR) and completed questionnaires that measured depressive symptoms and emotional impulsivity.
Structural equation modeling revealed that the s allele of 5-HTTLPR was related to greater depressive symptoms (β = .20, p < .042) but only marginally to greater emotional impulsivity (β = .19, p < .068). Depressive symptoms and emotional impulsivity were positively related (β = .33, p < .003). Further tests explored possible mediation from genotype to one psychological variable via the other. Results suggest that depressive symptoms, particularly perceived interpersonal rejection, may be a pathway linking genotype to emotional impulsivity.
Findings provide the first evidence that low serotonergic function contributes to both depression and impulsivity within a clinically meaningful sample. Furthermore, the link of s allele of 5-HTTLPR to emotional impulsivity was mediated by depressive symptoms, particularly perceptions of social rejection. Findings have implications for advanced breast cancer patients’ treatment decision.
KeywordsSerotonin transporter polymorphism (5-HTTLPR) Depressive symptoms Emotional impulsivity Advanced breast cancer Treatment decision
The authors extend their appreciation to all the study participants and the Dr. Susan Love Research Foundation’s Love/Avon Army of Women Program for their assistance in recruitment. The first author dedicates this research to the memory of Heekyoung Kim and Keun Meeso.
This study was funded by the National Cancer Institute (R01CA118567) and the National Center for Research Resources (UL1 RR025744) to DS. Writing of this manuscript was supported by American Cancer Society Research Scholar Grants (121909-RSG-12-042-01-CPPB) to YK.
Compliance with ethical standards
The study was carried out in accordance with the latest version of the Declaration of Helsinki and the study design was reviewed by the Stanford University Institutional Review Board. Informed consent of the participants was obtained after the nature of the procedures had been fully explained.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Beitchman, J. H., Davidge, K. M., Kennedy, J. L., Atkinson, L., Lee, V., Shapiro, S., & Douglas L. (2003). The serotonin transporter gene in aggressive children with and without ADHD and nonaggressive matched controls. Annals of New York Academy of Science, 1008, 248–251Google Scholar
- 3.Collier DA, Stöber G, Li T, Heils A, Catalano M, di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Müller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1:453–460PubMedGoogle Scholar
- 4.Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M (2005) The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 57:247–251CrossRefPubMedGoogle Scholar
- 18.Andersen BL, DeRubeis RJ, Berman BS, Gruman J, Champion VL, Massie MJ, Holland JC, Patridge AH, Bak K, Somerfield MR, Rowland JH (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605–1619CrossRefPubMedPubMedCentralGoogle Scholar
- 28.AMOS 21.0. (2012). SPSS Amos users’ guide, Version 21.0. IBMGoogle Scholar
- 42.Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671–1676CrossRefPubMedGoogle Scholar